The suPARnostic® Value Spectrum
All our studies have led to the suPARnostic® spectrum for interpretation of results. The spectrum depicts the three major decision areas of suPARnostic® measurement:
GREEN for a "healthy" individual, YELLOW for a patient to be observed and investigated further, RED for a critical patient in immediate need of attention and treatment.
It has been published that no genetic polymorphisms exist causing humans to naturally express high levels of suPAR, indicating that elevated concentrations of suPAR can be exclusively attributed to immune activation or immune response to a specific challenge.
Several thousand individuals were investigated in a population study to obtain the “healthy” baseline, which varies slightly depending on gender and age (see table on right side of spectrum). With age the healthy suPAR baseline rises and women have a slightly higher baseline than men – a fact that so far that has not been explained at the scientific level.
The definition of the yellow (“OBSERVATION”) and red (“CRITICAL”) range is based on all patients screened so far and their respective history and outcome. As work with suPARnostic® progresses and data are added to the statistical pool, the respective numbers and ranges for corresponding clinical read-out will become more and more precise.
Interpretation of suPARnostic® Values in Clinical Settings
(simplified guidelines)
Patient Triage (typically ER and pre-ER)
• “HEALTHY” per above spectrum and other standard clinical parameters: No acute care required
• “OBSERVATION” per above spectrum and other standard clinical parameters without pathological findings:
No need of acute attention, but observation and further investigation advisable; if suPARnostic® is rising further,
an acute condition is developing and swift action is advisable; if suPARnostic® stays constant at an elevated level, further investigation outside acute care might reveal an underlying condition
• “CRITICAL” per above spectrum: Immediate acute care attention advisable as mortality risk may be high
Patient Monitoring (typically ICU)
• “CRITICAL” per above spectrum: High mortality risk; if suPARnostic® does not decrease or continues to increase
in spite of treatment even if other common blood parameters normalize, modify treatment and/or investigate other potential pathologies as fast as possible
• “OBSERVATION” per above spectrum: Close monitoring of suPARnostic® advisable: Decreasing levels indicate
improvement and treatment response, increasing levels indicate worsening condition and insufficient treatment response; a complication could develop and perhaps be prevented
• suPARnostic® decreases to “HEALTHY” and stays there and other standard blood parameters are in the normal range: Discharge from acute care
